The effects of erdosteine on coagulation in rats

Basit Öğe Kaydı
dc.authorscopusid34875451400
dc.authorscopusid25723006200
dc.authorscopusid55960390600
dc.authorscopusid24474031200
dc.authorscopusid24081076900
dc.authorscopusid24167735400
dc.authorscopusid56236818900
dc.contributor.authorMotor, Sedat
dc.contributor.authorAlp, Harun
dc.contributor.authorYuksel, Rana
dc.contributor.authorErden, Ersin Sukru
dc.contributor.authorOktar, Suleyman
dc.contributor.authorCelik, Salih
dc.contributor.authorCayirci, Gokhan
dc.date.accessioned2024-09-19T15:41:24Z
dc.date.available2024-09-19T15:41:24Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground and objectives: Erdosteine, a thiol derivative in the same group as N-acetyl cysteine, belongs to a class of medicines called expectorants. Aim: It was aimed to determine effects of erdosteine (ERD) on coagulation. Material and methods: A total of 23 female rats were divided into three groups as control (C) (n=7), ERD-10 (n=7), ERD-50 (n=9). Rats in C group were given dilution of 0.3 ml sodium bicarbonate [NaHCO3]; rats in ERD-10 group were given 10 mg/kg ERD; and rats in ERD-50 group were given 50 mg/kg ERD. The drugs were given for ten days by oral gavage. Blood samples were drawn from the heart 24 hours after the last drug dose, and coagulation parameters were measured with automated analyzers. Results: While Factor VIII and AT-III levels decreased in both ERD-10 and ERD-50 group, Factor IX levels only decreased in ERD-50 group. Also, INR, PT and aPTT were prolonged in the ERD-50 group compared with the control and ERD-10 groups. There was no significant difference between groups for protein C and S. Conclusion: The results showed that erdosteine may increase bleeding tendencies in a dose-related manner. Therefore, we suggest that it should be noted when erdosteine is used together with anticoagulant medications. In addition, patients should be questioned regarding the use of erdosteine before dental or medical operations in order to prevent bleeding abnormalities.en_US
dc.identifier.endpage804en_US
dc.identifier.issn0393-6384
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84903482965en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage801en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14236
dc.identifier.volume30en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectActivated partial tromboplastin time (aPTT)en_US
dc.subjectAntithrombin IIIen_US
dc.subjectCoagulationen_US
dc.subjectErdosteineen_US
dc.subjectFactor IXen_US
dc.subjectFactor VIIIen_US
dc.subjectInternational normalized ratio (INR)en_US
dc.subjectProtein C and Sen_US
dc.subjectProtrombin time (PT)en_US
dc.titleThe effects of erdosteine on coagulation in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu